STAY UPDATED

We are committed to sharing the latest news and activities related to HDx therapy enabled by the THERANOVA dialyzer. Check out the latest news and events below.

ERA-EDTA.jpg
Event

ERA-EDTA European Renal Association

Visit us at the 54th annual ERA-EDTA congress for an experience that will explore what’s next in renal therapies.

VISIT EVENT WEBSITE
Madrid
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au

RSA_Australasia.jpg
Event

RSA Annual Conference

The theme for the annual conference is, “Renal care in a changing environment: Innovation and transformation”. We look forward to invite attendees to our Baxter booth and innovation room to discover the potential of our HDx therapy - the next innovation in hemodialysis therapy. We will also host a dinner symposium the day before discussing the latest advances in hemodialysis membrane technology: patient centered care with professor Colin Hutchison, Hawke’s Bay District Health Board, New Zealand. To register for this event, please log on to Baxter Professional and navigate to events. Registrations are limited. RSVP: 2nd June, 2017.

VISIT EVENT WEBSITE
SYDNEY
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au

Nordic_event.jpg
Event

Kongress für Nephrologie

Visit our Booth and Symposia at the 9th annual congress of the German Society of Nephrology.

VISIT EVENT WEBSITE
Mannheim
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au

Nordic_event.jpg
Event

Nordic Society of Nephrology

The Congress will be a great opportunity for participants to meet and discuss topics within nephrology and to further increase the co-operation between colleagues from our Nordic countries. Talk to our Baxter representatives at the Congress to learn more about HDx Therapy and how this new Therapy can benefit your patients.

VISIT EVENT WEBSITE
MALMÖ
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au

event-nephro-swiss.jpg
Event

Italian Society of Nephrology Annual Congress (SIN)

The Italian Society of Nephrology (SIN), established in 1980, has objectives of general interest and social utility to promote and enhance the field of Nephrology in all its aspects. Join us at this year’s Congress to find out more about HDx Therapy.

VISIT EVENT WEBSITE
RIMINI
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

event-nephro-swiss.jpg
Event

ASN Kidney week

Visit us the annual ASN congress to learn more what’s next in renal therapies.

VISIT EVENT WEBSITE
NEW ORLEANS, LOUISIANA
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

event-nephro-swiss.jpg
Event

SGN-SSN
Swiss Society of Nephrology

The 48th annual meeting of the Swiss Society of Nephrology will be another opportunity to find out more on the new HDx therapy.

VISIT EVENT WEBSITE
Interlaken
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

Swiss Launch image
News

The Middle Molecules Clearance App is now available in App Store

close

Middle Molecules Clearance App by Baxter proposes a categorization of middle molecules and a review of the treatment-related factors influencing dialytic removal of middle molecules, including membrane characteristics and solute removal mechanisms.

Swiss Launch image
News

New Data Demonstrates High Performance of HDx Enabled by THERANOVA

close

Baxter highlighted new data on its novel HDx therapy enabled by the THERANOVA dialyzer at the 54th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), June 3-6. Data from two independent studies concluded that HDx, or expanded hemodialysis therapy, enabled by the THERANOVA dialyzer effectively removed small and mid-sized toxins at similar rates when compared to hemodiafiltration (HDF), another type of dialysis.

See the press release here.

Swiss Launch image
News

HDx and THERANOVA was succesfully pre-launched at the KSN conference in Soul, Korea

close

More than 1,000 members of the nephrology community joined the Korea Society of Nephrology Congress. Baxter held a luncheon Symposium entitled “HDx therapy enbaled by THERANOVA: The medium cut-off (MCO) membrane with larger pores and higher selectivity to optimize middle molecule removal”. Dr KW Joo , Scientific Chair of the Symposia and also a senior member of Seoul National University Nephrology Dept., discussed the topic together with Dr Bernd Krause Sr Director of Membrane & Dialyzers R&D Baxter. The Symposia attracted over 200 visitors. If you are interested to learn more about HDx Therapy please contact your local Baxter representative here. Official launch in Korea is planned in July 2017.

Swiss Launch image
News

HDx therapy, enabled by THERANOVA, has been successfully launched in Swiss

close

The launch of HDx therapy enabled by THERANOVA took place at the 48th annual meeting of the Swiss Society of Nephrology in Interlaken from the 8th to the 9th of December 2016. Approx. 250 nephrologists attended the congress, and there was great excitement about this new therapy. Please contact a local Baxter representative to learn more.

News_thumbs_3.jpg
News

HDx therapy, enabled by THERANOVA, has been successfully launched in France

close

The launch of HDx therapy enabled by THERANOVA took place at the SFNDT Congress (Société Française de Néphrologie, Dialyse et Transplantation) in Strasbourg from the 4th to the 7th of October 2016.

The congress is a major event for the chronic kidney disease medical community, with about 1200 nephrologists present. France is the 1st country in Europe to have launched HDx therapy enabled by THERANOVA and the 2nd country worldwide after Australia.

News_thumbs_2.jpg
News

Baxter Launches HDx therapy Enabled by THERANOVA to Provide High Performance Hemodialysis Treatments

See the press release here
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

News_thumbs_1.jpg
News

HDx and THERANOVA was officially launched at the APCN / ANZSN conference in Perth Western Australia

close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

Sign up

Keep up to date with all our latest news, stories and events. By subscribing, you can learn more about our innovative therapy program, ongoing trials and results, and global research partnerships. Delivered right to your inbox.